Status:
COMPLETED
Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
Lead Sponsor:
British Thoracic Society
Conditions:
Pulmonary Diseases
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these s...
Eligibility Criteria
Inclusion
- Patients with pulmonary disease due to M.avium intracellulare, M.malmoense or M.xenopi. Aged 16 or over. With clinical and/or radiological evidence of active infection and producing sputum positive on culture on at least 2 occasions.
Exclusion
- Pregnant women and women of childbearing age not taking adequate contraceptive precautions.
- Patients who have sputum currently positive on culture for M.tuberculosis or M.bovis.
- Patients who have AIDS or who are known to be HIV positive
Key Trial Info
Start Date :
March 1 1995
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00367913
Start Date
March 1 1995
End Date
September 1 2004
Last Update
August 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Llandough Hospital
Penarth, Vale of Glamorgan, United Kingdom, CF64 2XX